Genzyme prepares for FDA visit

The FDA has informed Genzyme that it will visit the company's beleaguered Allston Landing manufacturing facility to follow up on a May inspection. The regulator indicated to the Boston biotech that all promised corrective and preventative actions identified in a February warning letter had not been either fully or adequately implemented at the time of the May inspection.

Genzyme said in an announcement that it will work with the FDA to schedule the visit.

During the re-inspection, the FDA will also review remediation efforts made in the wake of viral contamination that halted production of the drugs Fabrazyme and Cerezyme. As reported in late June, Genzyme expanded its vaporized hydrogen peroxide clean-up effort beyond the bioreactor involved to the entire manufacturing facility, temporarily shutting it down.

- here's the Genzyme announcement

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.